Details

Autor(en) / Beteiligte

• Gao, H. F.
• Liang, Y.
• Zhou, N. N.
• Zhang, D. S.
• Wu, H. Y.

Titel

Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy

Ist Teil von

• Internal medicine journal, 2013-01, Vol.43 (1), p.73-76

Ort / Verlag

Australia: Blackwell Publishing Ltd

Erscheinungsjahr

2013

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Background Chemotherapy‐induced nausea and vomiting remain among the most feared adverse effects for cancer patients. Aim The aim of this study was to evaluate the efficacy and safety of a combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in patients receiving multiple‐day cisplatin‐based chemotherapy. Methods Forty‐one solid cancer patients received aprepitant, palonosetron and dexa‐ methasone during a 3‐day cisplatin‐based chemotherapy. Primary end‐point was complete response in the overall phase (day 1 until 5 days after the end of chemotherapy). Results Aprepitant in combination with palonosetron and dexamethasone was safe, with hiccups (31.7%), fatigue (17.1%), headache (14.6%) and constipation (12.2%) the most common treatment‐related adverse events, mostly mild. Complete response was seen in 58.5% of patients in the overall phase. In 23 patients receiving aprepitant in combination with palonosetron and dexamethasone more than one cycle (range: 2–5 cycles), the cumulative emetic protection rate after five cycles was 0.82. Conclusion This study shows aprepitant in combination with palonosetron and dex‐amethasone is safe and effectively controls chemotherapy‐induced nausea and vomiting in patients undergoing 3‐day cisplatin‐based chemotherapy, moreover, the efficacy is maintained during multiple cycles.